Coeptis Therapeutics (NASDAQ:COEP) Trading Down 5% - What's Next?

Key Points

• The stock price of Coeptis Therapeutics (NASDAQ:COEP) dropped by 5%, finishing at $12.66 after trading as low as $12.50, with trading volume down 27% from average levels.
• Analysts upgraded Coeptis Therapeutics from a "sell" rating to a "hold" rating, potentially indicating a more favorable outlook for investors.
• Coeptis Therapeutics reported a quarterly loss of ($1.17) earnings per share and $0.20 million in revenue, highlighting ongoing financial challenges.

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Get Free Report) shares traded down 5% on Thursday . The stock traded as low as $12.50 and last traded at $12.66. 33,573 shares were traded during mid-day trading, a decline of 27% from the average session volume of 46,283 shares. The stock had previously closed at $13.32.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Coeptis Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd.

Coeptis Therapeutics Stock Performance

The firm has a market cap of $64.20 million, a PE ratio of -2.30 and a beta of -0.57. The business has a 50 day simple moving average of $10.68 and a two-hundred day simple moving average of $10.04. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of 0.02.

Coeptis Therapeutics (NASDAQ:COEP - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($1.17) EPS for the quarter. The firm had revenue of $0.20 million for the quarter.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.